Table 1 Epidemiological and clinical characteristics of the Omicron BA.5.2 and prototype patients

N

157

199

Gender

 male

81 (51.6%)

110 (55.3%)

0.479

0.489

 female

76 (48.4%)

89 (44.7%)

Age (years)

51.49 ± 17.39

51.49 ± 13.51

0.002

0.998

Smoking history

17 (10.8%)

34 (17.1%)

2.800

0.090

Comorbidity

 Hypertension

31 (19.7%)

44 (22.1%)

0.295

0.587

 Coronary heart disease

4 (2.5%)

11 (5.5%)

1.931

0.165

 COPD

1 (0.6%)

3 (1.5%)

0.599

0.439

 Pulmonary tuberculosis

1 (0.6%)

3 (1.5%)

0.599

0.439

 Chronic bronchitis

3 (1.9%)

3 (1.5%)

0.086

0.769

 Viral hepatitis

4 (2.5%)

3 (1.5%)

0.493

0.483

 Fatty liver

4 (2.5%)

2 (1.0%)

1.261

0.262

Signs and symptoms

 asymptomatic

2 (1.0%)

62 (31.2%)

53.140

< 0.001

 Fever

118 (75.2%)

85 (39.2%)

37.700

< 0.001

 Cough

94 (59.9%)

78 (39.2%)

15.030

< 0.001

 Fatigue

39 (24.8%)

8 (4.0%)

33.200

< 0.001

 Chest tightness/dyspnea

28 (17.8%)

2 (1.0%)

32.210

< 0.001

 Sore throat

13 (8.3%)

26 (13.1%)

2.060

0.001

 Headache

6 (3.8%)

21 (10.6%)

6.264

0.012

 Muscle soreness

22 (14.0%)

9 (4.5%)

9.092

0.002

 Nausea or vomiting

7 (4.5%)

5 (2.5%)

1.020

0.312

 Diarrhea

16 (10.2%)

4 (2.0%)

5.651

0.017

 Anorexia

28 (17.8%)

5 (2.5%)

10.070

0.001

Type of the novel coronavirus

 Mild/Common

112 (71.3%)

199 (100%)

65.290

< 0.001

 Severe/Critical

45 (28.7%)

0 (0.0%)

T (℃)

37.8 ± 0.93

37.37 ± 0.98

3.948

< 0.001

Mortality

11 (7.0%)

0 (0.0%)

14.390

< 0.001